Artificial CSF Infusion for Glaucoma Pressure Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current glaucoma treatments, particularly for primary open-angle glaucoma, are inadequate as they often fail to sufficiently lower intraocular pressure, leading to disease progression and are associated with significant side effects and complications, necessitating an alternative approach that addresses raised intraocular pressure and reduced intracranial pressure.
Innovation Solution
The method involves administering artificial cerebrospinal fluid (CSF) or a CSF-like solution to increase intracranial pressure and cerebrospinal fluid turnover through an implantable pump system, which infuses the fluid into the intrathecal space or cerebral ventricles to reduce the trans-lamina cribrosa pressure difference and enhance CSF clearance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stress or pressure
If medication is administered to lower intraocular pressure, then intraocular pressure is reduced, but the reduction is insufficient (at most 25-30%) and side effects occur
Solution Approach 1:
The patent introduces an intermediary substance (viscoelastic material) that mediates between the intraocular space and the episcleral veins, creating a new drainage pathway for aqueous humor. This intermediary material forms a controlled leak site that bypasses the blocked conventional drainage routes, thereby achieving more effective pressure reduction without the limitations of medication.
Solution Approach 2:
The invention applies hydraulic principles by creating a fluid dynamics-based drainage system. The viscoelastic material creates a controlled hydraulic leak site that allows aqueous humor to flow from the anterior chamber through the sclera into the episcleral veins, utilizing pressure gradients and fluid flow mechanics to achieve sustained intraocular pressure reduction.
2Stress or pressure
If topical medications are used for glaucoma treatment, then intraocular pressure is lowered, but side effects such as asthma, bradycardia, impotence, and decreased exercise tolerance occur
Solution Approach 1:
The patent extracts the therapeutic function of pressure reduction from systemic/topical medications and implements it through a localized mechanical drainage enhancement. By taking out the need for pharmacological intervention and replacing it with a physical drainage modification, the invention eliminates the harmful side effects associated with topical medication while maintaining the beneficial pressure-lowering effect.
3Stress or pressure
If incisional surgery is performed to treat glaucoma, then intraocular pressure is reduced, but complications such as choroidal effusion, hypotony maculopathy, suprachoroidal haemorrhage, and bleb infections occur
Solution Approach 1:
Instead of creating a large incisional opening in the conventional drainage pathway (trabeculotomy), the invention inverts the approach by creating a controlled leak site through the sclera away from the cornea and anterior chamber. This reverse approach avoids the complications of incisional surgery by establishing drainage through a different anatomical route with fewer risks of hemorrhage, effusion, and infection.
4Stress or pressure
If frequent dosing regimens are used for glaucoma medication, then intraocular pressure control is attempted, but compliance problems occur
Solution Approach 1:
The invention transforms the discontinuous action of frequent medication dosing into a continuous passive drainage enhancement. The viscoelastic material provides ongoing, continuous facilitation of aqueous humor outflow without requiring repeated patient actions, thereby ensuring consistent pressure control and eliminating compliance issues associated with frequent dosing schedules.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively treats and prevents glaucoma by increasing intracranial pressure and CSF turnover, reducing the trans-lamina cribrosa pressure difference, thereby mitigating optic nerve damage and visual field progression with fewer side effects compared to traditional treatments.
Implementation Method 1
The pump is configured to deliver the artificial CSF to the intrathecal space or the cerebral ventricles at a rate sufficient to increase the intracranial pressure
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
Described herein is the use of CSF, more particularly external CSF or CSF-like compositions for the treatment and prevention of Glaucoma. More particularly, the application provides for the administration of CSF to the intrathecal space or the cerebral ventricles of a patient to increase intracranial pressure and/or CSF flow. The application further provides adjusted methods and tools for the treatment and prevention of Glaucoma.